Botulinum toxin in neuro‐urological disorders
Identifieur interne : 003D95 ( Main/Exploration ); précédent : 003D94; suivant : 003D96Botulinum toxin in neuro‐urological disorders
Auteurs : Wolfgang H. Jost [Allemagne] ; Markus Naumann [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug effects : Reflex, Abnormal.
- drug therapy : Urologic Diseases.
- Humans, Treatment Outcome, Urology.
Abstract
Botulinum toxin has been used in urology since the end of the 1980s. However, this therapeutic option has not been firmly established yet. Valid studies have merely been conducted on detrusor sphincter dyssynergia (DSD) and on detrusor overactivity (hyperreflexia), but even those findings do not allow final conclusions. Success rates in DSD are between 58% and 88%, in detrusor overactivity approximately 80%. Further possible indications for botulinum toxin are motor and sensory urge, urethrospasm, spasticity of the pelvic floor, neobladder, and even chronic prostatic pain. To reach firmer conclusions, controlled studies with well‐defined patient populations and using validated and reproducible outcome measures are needed. In addition, we also need information on repeated injections over a long period of time. These data are not available to date. At present, the application of botulinum toxin should be reserved for experienced users only. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20068
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002D87
- to stream Istex, to step Curation: 002D87
- to stream Istex, to step Checkpoint: 002776
- to stream PubMed, to step Corpus: 003500
- to stream PubMed, to step Curation: 003500
- to stream PubMed, to step Checkpoint: 003543
- to stream Ncbi, to step Merge: 000D84
- to stream Ncbi, to step Curation: 000D84
- to stream Ncbi, to step Checkpoint: 000D84
- to stream Main, to step Merge: 005753
- to stream PascalFrancis, to step Corpus: 002248
- to stream PascalFrancis, to step Curation: 000A73
- to stream PascalFrancis, to step Checkpoint: 002227
- to stream Main, to step Merge: 005A65
- to stream Main, to step Curation: 003D95
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin in neuro‐urological disorders</title><author><name sortKey="Jost, Wolfgang H" sort="Jost, Wolfgang H" uniqKey="Jost W" first="Wolfgang H." last="Jost">Wolfgang H. Jost</name></author><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:36977C5C9DD52E44A4DC84819C5ADF44B0798917</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20068</idno><idno type="url">https://api.istex.fr/document/36977C5C9DD52E44A4DC84819C5ADF44B0798917/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002D87</idno><idno type="wicri:Area/Istex/Curation">002D87</idno><idno type="wicri:Area/Istex/Checkpoint">002776</idno><idno type="wicri:doubleKey">0885-3185:2004:Jost W:botulinum:toxin:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15027067</idno><idno type="wicri:Area/PubMed/Corpus">003500</idno><idno type="wicri:Area/PubMed/Curation">003500</idno><idno type="wicri:Area/PubMed/Checkpoint">003543</idno><idno type="wicri:Area/Ncbi/Merge">000D84</idno><idno type="wicri:Area/Ncbi/Curation">000D84</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D84</idno><idno type="wicri:doubleKey">0885-3185:2004:Jost W:botulinum:toxin:in</idno><idno type="wicri:Area/Main/Merge">005753</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0228274</idno><idno type="wicri:Area/PascalFrancis/Corpus">002248</idno><idno type="wicri:Area/PascalFrancis/Curation">000A73</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002227</idno><idno type="wicri:doubleKey">0885-3185:2004:Jost W:botulinum:toxin:in</idno><idno type="wicri:Area/Main/Merge">005A65</idno><idno type="wicri:Area/Main/Curation">003D95</idno><idno type="wicri:Area/Main/Exploration">003D95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin in neuro‐urological disorders</title><author><name sortKey="Jost, Wolfgang H" sort="Jost, Wolfgang H" uniqKey="Jost W" first="Wolfgang H." last="Jost">Wolfgang H. Jost</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden</wicri:regionArea><wicri:noRegion>Wiesbaden</wicri:noRegion><wicri:noRegion>Wiesbaden</wicri:noRegion></affiliation></author><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S142">S142</biblScope><biblScope unit="page" to="S145">S145</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">36977C5C9DD52E44A4DC84819C5ADF44B0798917</idno><idno type="DOI">10.1002/mds.20068</idno><idno type="ArticleID">MDS20068</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Bontoxilysin</term><term>Botulinum Toxins (therapeutic use)</term><term>Humans</term><term>Nervous system diseases</term><term>Reflex, Abnormal (drug effects)</term><term>Treatment Outcome</term><term>Urologic Diseases (drug therapy)</term><term>Urology</term><term>botulinum toxin</term><term>detrusor</term><term>hyperreflexia</term><term>urology</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Reflex, Abnormal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Urologic Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Treatment Outcome</term><term>Urology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Botulinum toxin has been used in urology since the end of the 1980s. However, this therapeutic option has not been firmly established yet. Valid studies have merely been conducted on detrusor sphincter dyssynergia (DSD) and on detrusor overactivity (hyperreflexia), but even those findings do not allow final conclusions. Success rates in DSD are between 58% and 88%, in detrusor overactivity approximately 80%. Further possible indications for botulinum toxin are motor and sensory urge, urethrospasm, spasticity of the pelvic floor, neobladder, and even chronic prostatic pain. To reach firmer conclusions, controlled studies with well‐defined patient populations and using validated and reproducible outcome measures are needed. In addition, we also need information on repeated injections over a long period of time. These data are not available to date. At present, the application of botulinum toxin should be reserved for experienced users only. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Basse-Franconie</li></region><settlement><li>Wurtzbourg</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Jost, Wolfgang H" sort="Jost, Wolfgang H" uniqKey="Jost W" first="Wolfgang H." last="Jost">Wolfgang H. Jost</name></noRegion><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:36977C5C9DD52E44A4DC84819C5ADF44B0798917
|texte= Botulinum toxin in neuro‐urological disorders
}}
| This area was generated with Dilib version V0.6.23. |  |